This is the authors' abstract. We don't add key points for this paper.
IL-17, IL-12/23, and IL-23 inhibitors had high efficacy in the achievement of PASI 75, PASI 100, and sPGA 0/1 or IGA 0/1 or PGA 0/1 in moderate to severe plaque psoriasis after 12 or 16 weeks of treatment. IL-17 inhibitors showed superior efficacy. However, its clinical safety was poor. Risankizumab appeared to have relatively high efficacy and low risk. The clinical tolerance of other biological agents needs to be further observed.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: